(2023)
The role of pneumococcal extracellular vesicles on the pathophysiology of the kidney disease hemolytic uremic syndrome.
mSphere 8(4),
e0014223.
Prof. Dr. Peter F. Zipfel
Infection Biology · Head International Leibniz Research School · Speaker +49 3641 532-1301 peter.zipfel@leibniz-hki.deCurriculum vitae
Main Research Areas
- Immune escape of human pathogenic micro-organisms
- Infection-associated function of the complement system
- Genetic susceptibility for infections
Professional Career
Since 2000 | Professor for infection biology, Friedrich-Schiller-University Jena (FSU Jena) |
Since 2000 | Head of the department infection biology, Leibniz-Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute Jena |
1999 | Nontenured professor, University Hamburg |
1993 | Habilitation in immunology and molecular biology, University Hamburg |
1989-2000 | Group head at the Bernhard-Nocht-Institute for tropical medicine Hamburg |
1989 | Visiting associate, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, Maryland, USA |
1985-1988 | Postdoc, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, Maryland, USA, funded by the German Academic Exchange Service (DAAD) |
1984 | PhD as Dr. rer. nat., University Bremen |
1980-1985 | Research assistant, University Bremen |
1980 | Diploma in biology, University Bremen |
Awards · Appointments · Scientific Activities
Since 2009 | Member at the editorial board of molecular immunology, frontiers in innate immunity |
2009 | Excellence award from the Deutsche Gesellschaft für Hygiene und Mikrobiologie |
Since 2008 | Representative of the graduate school International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS) |
2008 | EFIS lecture award of the European Federation of Immunological Societies |
Since 2007 | Principal investigator of the excellence graduate school Jena School for Microbial Communication (JSMC) |
2007 | Heinz Spitzbart award of the European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG) |
Since 2006 | Principal investigator of the graduate school International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS) |
2007-2011 | President of the European Complement Network |
2005 – 2012 | Board member of the European Complement Network |
2004 | Thuringian research award |
Since 2002 | Deputy Director of the Leibniz-Institute for Natural Product Research and Infection Biology – Hans-Knöll-Institute Jena |
Since 2000 | Project leader for infection biology, L2 |
1999-2001 | Member at the editorial board of experimental and clinical immunology, thrombosis and haemostasis, section editor molecular immunology Member of the European Working Party on the Genetics of Complement mediated Kidney Diseases, Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM), Deutsche Gesellschaft für Immunologie, Gesellschaft für Genetik, Gesellschaft für Nephrologie |
Publications
(2023)
Increased plasma level of terminal complement complex in AMD patients: potential functional consequences for RPE cells.
Front Immunol 14,
1200725.
(2023)
Enolase 1 of Candida albicans binds human CD4+ T cells and modulates naïve and memory responses.
Eur J Immunol 53(11),
e2250284.
(2023)
Soluble enolase 1 of Candida albicans and Aspergillus fumigatus stimulates human and mouse B cells and monocytes.
J Immunol 211(5),
804-815.
(2023)
Sequence variation of Candida albicans Sap2 enhances fungal pathogenicity via complement evasion and macrophage M2-like phenotype induction.
Adv Sci (Weinh) 10(20),
e2206713.
(2023)
Kidney biopsy findings in patients with SARS-CoV-2 infection or after COVID-19 vaccination.
Clin J Am Soc Nephrol 18(5),
613-625.
(2023)
The classical pathway triggers pathogenic complement activation in membranous nephropathy.
Nat Commun 14(1),
473.
(2023)
The choline-binding proteins PspA, PspC, and LytA of Streptococcus pneumoniae and their interaction with human endothelial and red blood cells.
Infect Immun 91(9),
e0015423.
(2023)
[Role of Complement in Kidney Diseases - New Aspects].
Dtsch Med Wochenschr 148(12),
774-779.
(2022)
Breast cancer cell-based ELISA: a potential material for better detection of heparin-induced thrombocytopenia antibodies.
J Mater Chem B 10(38),
7708-7716.